- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2090-6226
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Artificial intelligence in nonalcoholic fatty liver disease ; volume:12 ; number:1 ; day:27 ; month:12 ; year:2022 ; pages:1-11 ; date:12.2022
Egyptian liver journal ; 12, Heft 1 (27.12.2022), 1-11, 12.2022
- Urheber
-
Mahzari, Ali
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s43066-022-00224-w
- URN
-
urn:nbn:de:101:1-2023030821123512097213
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mahzari, Ali
- SpringerLink (Online service)
Ähnliche Objekte (12)
Non-alcoholic fatty liver disease
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Hepatic Innervations and Nonalcoholic Fatty Liver Disease
Multiomics study of nonalcoholic fatty liver disease
Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?
Role of bioactive fatty acids in nonalcoholic fatty liver disease
Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease
Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease, diet and gut microbiota
Nonalcoholic fatty liver disease and cardiovascular disease risk
Resveratrol inhibits nonalcoholic fatty liver disease in rats
Non-alcoholic fatty liver disease
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Hepatic Innervations and Nonalcoholic Fatty Liver Disease
Multiomics study of nonalcoholic fatty liver disease
Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?
Role of bioactive fatty acids in nonalcoholic fatty liver disease
Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease
Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease, diet and gut microbiota
Nonalcoholic fatty liver disease and cardiovascular disease risk
Resveratrol inhibits nonalcoholic fatty liver disease in rats
Non-alcoholic fatty liver disease
Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity
Hepatic Innervations and Nonalcoholic Fatty Liver Disease
Multiomics study of nonalcoholic fatty liver disease
Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?
Role of bioactive fatty acids in nonalcoholic fatty liver disease
Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease
Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease, diet and gut microbiota
Nonalcoholic fatty liver disease and cardiovascular disease risk